Viruses, Vol. 12, Pages 1139: In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses
Viruses, Vol. 12, Pages 1139: In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses
Viruses doi: 10.3390/v12101139
Authors:
Liva Checkmahomed
Blandine Padey
Andrés Pizzorno
Olivier Terrier
Manuel Rosa-Calatrava
Yacine Abed
Mariana Baz
Guy Boivin
Two antiviral classes, the neuraminidase inhibitors (NAIs) and polymerase inhibitors (baloxavir marboxil and favipiravir) can be used to prevent and treat influenza infections during seasonal epidemics and pandemics. However, prolonged treatment may lead to the emergence of drug resistance. Therapeutic combinations constitute an alternative to prevent resistance and reduce antiviral doses. Therefore, we evaluated in vitro combinations of baloxavir acid (BXA) and other approved drugs against influenza A(H1N1)pdm09 and A(H3N2) subtypes. The determination of an effective concentration inhibiting virus cytopathic effects by 50% (EC50) for each drug and combination indexes (CIs) were based on cell viability. CompuSyn software was used to determine synergism, additivity or antagonism between drugs. Combinations of BXA and NAIs or favipiravir had synergistic effects on cell viability against the two influenza A subtypes. Those effects were confirmed using a physiological and predictive ex vivo reconstructed human airway epithelium model. On the other hand, the combination of BXA and ribavirin showed mixed results. Overall, BXA stands as a good candidate for combination with s...
Source: Viruses - Category: Virology Authors: Liva Checkmahomed Blandine Padey Andr és Pizzorno Olivier Terrier Manuel Rosa-Calatrava Yacine Abed Mariana Baz Guy Boivin Tags: Article Source Type: research
More News: Epidemics | Epidemiology | Flu Pandemic | H1N1 | H3N2 | Influenza | Oseltamivir | Pandemics | Tamiflu | Virology